Maze Therapeutics, Inc.
mazetx.comWhat Do They Do?
Develops small-molecule precision medicines for patients with kidney and metabolic diseases, using genetic research to guide drug discovery and development.
10-K for FY2025, filed Mar 25, 2026We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision…View ↗
Who Are Their Customers?
Biotechnology and pharmaceutical companies license drug programs discovered through Maze’s platform.
10-K for FY2025, filed Mar 25, 2026Our Compass platform supports end-to-end variant identification and functionalization capabilities as well as advanced research tools and…View ↗
The Company assessed the Trace License Agreement in accordance with ASC 606 and concluded that it was a contract with a customer. The…View ↗
The Company assessed the Shionogi License Agreement in accordance with ASC 606 and concluded that it was a contract with a customer. The…View ↗
The Company assessed the Neurocrine License Agreement in accordance with ASC 606 and concluded that it was a contract with a customer. The…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 11, 2026
−$44.7MView ↗
- ▲ +33% (Loss)
- vs −$33.7M in Q2 FY2025
-
Apr 22, 2026
Maze completed a registered stock and warrant offering
The offering raised gross proceeds of $150 million, intended primarily to fund research and development and general corporate purposes.
Sources
8-K, filed Apr 22, 2026
Maze Therapeutics Announces $150 Million Registered OfferingView ↗
Loading...
